DFG approves funding for 10 new clinical trials in 2015

December 17, 2015

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) has approved funding for six new clinical trials. This was decided by the Senate during its December meeting. Four other clinical trials were approved by the Senate in June. The topics of the ten contributions to medical research cover the fields of surgery, nephrology, gastroenterology, ophthalmology, dentistry, hospital hygiene and psychotherapy. The trials will investigate, among other topics, new therapeutic procedures for esophageal cancer and acute kidney failure, the role of cannabis in the management of tic disorders, and the treatment of obesity. Over 3,000 patients will participate in the trials.

The DFG's clinical trials programme enables researchers to address current, urgent questions in patient-oriented clinical research within the framework of a controlled interventional trial. All the approved trials are prospective and confirmatory trials on new procedures. This encompasses therapy trials, including pharmacological trials, as well as prognostic and diagnosis trials in phases II-IV.

The ten trials will receive a total of 13.1 million euros in funding for an initial period of three years. In total the DFG has already approved more than 80 clinical trials through this programme.

The topics of the new clinical trials (in alphabetical order by principal investigator):

Private lecturer Dr. Christian Bojarski, Charité - Universitätsmedizin Berlin

Prospective, double-blind diagnostic study of confocal laser endomicroscopy (CLE) for wheat sensitivity (WS) in patients with irritable bowel syndrome

Professor Dr. Iris F. Chaberny, University Hospital Leipzig

EFFECT of daily washing with Octenidine impregnated wash-cloths on the incidence of nosocomial infections in intensive care - a cross-over trial randomising intensive care units

Professor Dr. Sascha Fauser, University Hospital Cologne

Prophylactic intraoperative adjuvant therapy with 5-fluorouracil and low molecular weight heparin for the prevention of proliferative vitreoretinopathy (PVR) in high-risk patients with primary rhegmatogenous retinal detachment

Professor Dr. Petra Christine Gierthmühlen, Medical Center - University of Freiburg

CAD/CAM composite vs ceramic minimal invasive therapeutical intervention of severe non carious lesions: Clinical performance and quality of life improvement

Private lecturer Dr. Albrecht Hoffmeister, University Hospital Leipzig

A multi-centred, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liner vs intragastric balloons vs a sham procedure

Professor Dr. Ulrich T. Hopt, Medical Center - University of Freiburg

Perioperative chemotherapy (FLOT Protocol) compared with neoadjuvant chemoradiation (CROSS Protocol) in patients with adenocarcinoma of the esophagus

Professor Dr. Kirsten Müller-Vahl, Hannover Medical School

Randomized double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders

Professor Dr. Christian Plewnia, University Hospital Tübingen

Treatment of auditory hallucinations in schizophrenia with bilateral theta burst stimulation

Professor Dr. Thomas Seufferlein, Ulm University Medical Center

Allogenic microbiota-reconstitution (AMR) for the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial

Professor Dr. Alexander Zarbock, University Hospital Münster

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH-Trial)
-end-
Further Information

Media contact:


DFG Press and Public Relations, Tel. +49 228 885-2443, presse@dfg.de

DFG programme contacts:

Dr. Katja Großmann, Tel. +49 228 885-2565, Katja.Grossmann@dfg.de

Dr. Eckard Picht, Tel. +49 228 885-2028, Eckard.Picht@dfg.de

Detailed information will also be provided by the principal investigators of the clinical trials.

For more information about the DFG's programme for clinical trials, please visit:

http://www.dfg.de/clinical_trials

Deutsche Forschungsgemeinschaft

Related Esophageal Cancer Articles from Brightsurf:

Pathological regression of lymph nodes better predicts esophageal cancer survival
A team of researchers led by Osaka University established a new pathological grading system to evaluate the therapeutic effect of neoadjuvant chemotherapy (NAC) for metastatic lymph nodes (LNs) removed in esophageal cancer (EC) surgery, demonstrating that the system predicts recurrence and prognosis in EC patients better than conventional systems.

Racial disparities in surgery rates for esophageal cancer
Black patients with esophageal cancer are less likely to receive life-saving surgery for early-stage disease than white patients.

Portable 'electronic nose' can accurately pick up esophageal cancer precursor
A portable 'electronic nose' can accurately pick up the precursor condition to food pipe (esophageal) cancer, known as Barrett's esophagus, indicates a proof of principle study, published online in the journal Gut.

A new machine learning approach detects esophageal cancer better than current methods
Dartmouth scientists have proposed a new machine learning model for identification of esophageal cancer that could open new avenues for applying deep learning to digital pathology.

Lymph nodes can predict survival in patients with esophageal cancer
It is difficult for physicians to estimate recurrence and survival in patients with esophageal cancer.

New model improves staging and risk predictions for esophageal cancer patients
A new nomogram for assessing metastatic risk in esophageal cancer patients shows promise for more accurate risk-stratification, which is particularly relevant for stage T2 patients.

Combo of virotherapy and radiotherapy shows early promise in patients with esophageal cancer
The experimental oncolytic adenovirus telomelysin (OBP-301) in combination with radiotherapy was safe and showed early clinical efficacy in vulnerable patients with esophageal cancer, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3.

Drinking hot tea linked with elevated risk of esophageal cancer
Previous studies have revealed a link between hot tea drinking and risk of esophageal cancer, but until now, no study has examined this association using prospectively and objectively measured tea drinking temperature.

Test for esophageal cancer could save millions of lives
Cancer of the esophagus claims more than 400,000 lives around the world each year.

Genome offers clues to esophageal cancer disparity
A change in the genome of Caucasians could explain much-higher rates of the most common type of esophageal cancer in this population, a new study finds.

Read More: Esophageal Cancer News and Esophageal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.